二甲双胍对2型糖尿病患者血清PSA水平的影响及其与前列腺癌的关系  

Effect of metformin on plasma PSA level of type 2 diabetes and the relationship between metformin and prostate cancer

作　　者：郭颖[1] 吴波[1] 

机构地区：[1]中国医科大学附属盛京医院第一内分泌病房,沈阳110004

出　　处：《实用药物与临床》2015年第4期412-414,共3页Practical Pharmacy and Clinical Remedies

摘　　要：目的观察二甲双胍对2型糖尿病(T2DM)患者PSA水平的影响,并探讨二甲双胍与前列腺癌的关系。方法将2014年1-8月在我院内分泌科住院的178例T2DM男性患者和96例健康体检男性分为糖尿病组和健康对照组。糖尿病组和健康对照组(年龄和民族匹配)均排除既往或同时患有前列腺疾病或其他恶性肿瘤、急性感染(包括活动性的结核)和严重的肝肾功能损害者,对收集的临床资料和相关的辅助检查结果行回顾性的病例对照分析。结果 1糖尿病组PSA水平低于对照组(P<0.05)。2T2DM患者中,应用二甲双胍者的总PSA水平及游离PSA水平低于非二甲双胍组(P<0.01,P<0.05)。结论 T2DM患者血清PSA水平低于健康人群,二甲双胍可能有降低前列腺癌风险的作用。Objective To observe the effect of metformin on plasma PSA of T2 DM patients,and explore the relationship between metformin and prostate cancer. Methods 178 cases of T2 DM male patients of Department of Endocrinology in our hospital from January to August 2014 were collected as experimental group,and 96 healthy men were chose as control group. Patients with previous or simultaneous with prostate disease or other malignant tumor,acute infection（ including active tuberculosis） and serious liver and kidney injury were excluded. The retrospective casecontrol analysis for the clinical data and related auxiliary examination results of the cases in the tw o groups were done. Results 1 The level of PSA in experimental group was low er than that of control group（ P〈0. 05）. 2 In T2DM patients,the total PSA and free PSA levels in patients using metformin were obviously low er than the patients without using metformin group（ P〈0. 01,P〈0. 05）. Conclusion The plasma PSA level in patients with T2 DM was low er than that of healthy people,and metformin may reduce the risk of prostate cancer.

关 键 词：二甲双胍 2型糖尿病 PSA 前列腺癌 

分 类 号：R737.25[医药卫生—肿瘤] R587.1[医药卫生—临床医学]